Status:
COMPLETED
Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma
Lead Sponsor:
University of Cologne
Conditions:
Non-Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study aims to assess the short term efficacy of a combination of rituximab and low-dose radiotherapy in patients with non-Hodgkin's lymphoma.
Detailed Description
Rituximab and low-dose total-nodal irradiation both have shown promising activity in patients with NHL. Moreover, the radiolabelled antibody Zevalin has been approved for the treatment of relapsed NHL...
Eligibility Criteria
Inclusion
- B-cell non-Hodgkin's lymphoma
- At least one prior antitumor therapy
- ECOG performance status 0-2
- No major organ dysfunction
- Written informed consent
Exclusion
- The following histologies are excluded: Burkitt's lymphoma, mantle-cell lymphoma, primary CNS-lymphoma, HIV-associated lymphoma
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00147953
Start Date
June 1 2004
Last Update
January 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Cologne
Cologne, North Rhine-Westphalia, Germany, 50924